NCT06023758
Recruiting
Phase 2
A Multicenter II Study to Compare KN026 and KN046 Versus Oxaliplatin, Capecitabine Combined KN026 and KN046 in Patients With HER2-positive Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.
Peking University1 site in 1 country18 target enrollmentStarted: September 22, 2023Last updated:
Overview
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Peking University
- Enrollment
- 18
- Locations
- 1
- Primary Endpoint
- pCR rate
Overview
Brief Summary
This is a multicenter II study to compare KN026 and KN046 versus Oxaliplatin, Capecitabine combined KN026 and KN046 in patients with HER2-positive locally advanced resectable gastric cancer or gastroesophageal junction adenocarcinoma.
Detailed Description
KN026 is an anti-HER2 bispecific antibody that can simultaneously bind two non-overlapping epitopes of HER2, resulting in dual HER2 signaling blockade.KN046 is a PD-L1 - CTLA-4 bispecific antibody. The trial consists of two groups. All subjects will be treated with KN026 at 30 mg/kg Q3W in combination with KN046 at 5 mg/kg Q3W in Group 1. If the statistical hypothesis is not met in Group 1, patients will be enrolled in Group 2. Patients in group 2 will receive KN026+KN046+XELOX.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Sequential
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •The subject can understand the informed consent, voluntarily participate and sign the informed consent ;
- •Subjects are older than or equal to 18 years old and younger than or equal to 75 years old on the day of signing the informed consent；
- •Histologically or cytologically confirmed, locally advanced HER2-positive gastric cancer or gastroesophageal junction adenocarcinoma.
- •ECOG score 0 or 1;
- •Left ventricular ejection fraction (LVEF) ≥ 50% at baseline as determined by either ECHO (preferred) or MUGA;
- •Liver function met the following criteria within 7 days prior to initial administration:
- •Total bilirubin ≤1.0x ULN (Gilbert's syndrome, or total bilirubin ≤1.5x ULN in liver metastases); Aminotransferase (ALT/AST) ≤1.5x ULN (liver metastatic subjects ≤3xULN); -Renal function within 7 days prior to initial administration: serum creatinine ≤1.5x ULN and serum creatinine clearance ≥60mL/min (according to Cockcroft-Gault Formula calculation);
- •Bone marrow function met the following criteria within 7 days prior to initial administration: Hemoglobin ≥90 g/L; Neutrophil absolute count ≥1.5 x 109/L; Platelet count ≥100x 109/L; INR or PT≤1.5x ULN, and aPTT≤ 1.5x ULN;
- •Life expectancy \>3 months;
- •The subjects are able and willing to follow the visits, treatment plans, laboratory tests, and other study-related procedures specified in the study protocol
Exclusion Criteria
- •Existence of other active malignant tumors within 5 years or at the same time. Plan to perform or have undergone an organ or bone marrow transplant. Myocardial infarction and poorly controlled arrhythmias occurred within 6 months prior to the first dose.
- •Existence of grade III - IV cardiac disorders defined by the NYHA or echocardiogram shows: LVEF (left ventricular ejection fraction) \< 50%.
- •Human immunodeficiency virus (HIV) infection.
- •Patients with active tuberculosis.
- •Patient with previous or current interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-associated pneumonia, severely impaired lung function, etc.
- •Patients who have previously received other antibody/drug treatments for immune checkpoints, such as PD-1, PD-L1, and CTLA4 treatments.
- •Have diseases that may increase the risk of participating in the study and using the study medications, or other severe, acute, and chronic diseases and therefore are judged by the investigator to be unsuitable for clinical studies.
Arms & Interventions
KN026 combined with KN046
Experimental
KN026 combined with KN046
Intervention: KN026 (Drug)
KN026 combined with KN046
Experimental
KN026 combined with KN046
Intervention: KN046 (Drug)
KN026，KN046 and XELOX
Experimental
KN026，KN046 and XELOX
Intervention: KN026 (Drug)
KN026，KN046 and XELOX
Experimental
KN026，KN046 and XELOX
Intervention: KN046 (Drug)
KN026，KN046 and XELOX
Experimental
KN026，KN046 and XELOX
Intervention: XELOX (Drug)
Outcomes
Primary Outcomes
pCR rate
Time Frame: up to 2 years
Pathological complete response (pCR) rate (assessed by central pathology laboratory and the site)
Secondary Outcomes
- Event-free survival (EFS)(from enrollment until firstly confirmed and recorded disease progression or death，assessed up to 3 years)
- Disease-free survival (DFS)(from the start of surgery to disease recurrence or death (for any reason)，assessed up to 3 years)
- overall survival (OS)(From date of randomization until the date of death from any cause, assessed up to 5 years)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Unknown
Phase 2
Study of KN046 With Chemotherapy in First Line Advanced NSCLCNon-small Cell Lung CancerNCT04054531Jiangsu Alphamab Biopharmaceuticals Co., Ltd50
Completed
Phase 1
A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast CancerTriple-negative Breast CancerNCT03872791Jiangsu Alphamab Biopharmaceuticals Co., Ltd52
Unknown
Phase 2
Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast CancerBreast CancerNCT04881929Jiangsu Alphamab Biopharmaceuticals Co., Ltd30
Completed
Phase 2
Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT02434744Response Pharmaceuticals121
Terminated
Phase 2
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney CancerMetastatic Kidney CarcinomaRecurrent Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v7Stage IV Renal Cell Cancer AJCC v7NCT01239342National Cancer Institute (NCI)43